Transdermal testosterone therapy: a potential treatment for selective serotonin reuptake inhibitor (SSRI)-associated sexual dysfunction in women

女性性功能障碍（FSD）经常报告与选择性5-羟色胺再摄取抑制剂（SSRI）治疗和文拉法辛，这些是澳大利亚妇女使用的最常见的抗抑郁药。我们已经证明，睾酮治疗显著改善女性FSD患者的性功能。然而，SSRI使用者被排除在这些过去的研究之外。本研究的目的是评估经皮睾酮治疗与SSRI治疗相关的性功能障碍的疗效。

Female sexual dysfunction (FSD) is frequently reported with selective serotonin reuptake inhibitor (SSRI) therapy and venlafaxine, these being the most common antidepressants used by Australian women. We have shown that testosterone therapy significantly improves sexual function in women with FSD. However SSRI-users have been excluded from these past studies. The aim of this study is to assess the efficacy of transdermal testosterone therapy for treatment of sexual dysfunction associated with SSRI therapy.